Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy

Recruiting N/A Interventional Study
Depression - Major Depressive Disorder Bipolar Disorder (BD) Functional Magnetic Resonance Imaging (fMRI) Cognition Autobiographical Memory Electroconvulsive Therapy ECT Treatment Outcome Inpatients
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
145 (estimated)
Sponsor
Anders Jørgensen · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and/or zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without diminishing treatment effectiveness in hospitalized patients with depression. The investigators hypothesize that blockade of the GABA receptor with flumazenil will reduce cognitive…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: * Current depressive episode (unipolar or bipolar), corresponding to ICD-10 codes F31.3-5, F32 or F33. * Admitted at a study affiliated department in the Mental Health Services of the Capital Region of Denmark * Referred to ECT by the regular psychiatrist and has given consent t…
Contacts

Stella K. S. Lystlund, MSc in Psychology

+ 45 21 35 40 55

stella.klara.soerensdottir.lystlund@regionh.dk

CONTACT

Yunus Kiros, MD

+ 45 81 71 95 29

yunus.kiros.02@regionh.dk

CONTACT